Sky9 Capital Announces the Addition of Chay, Teh, Xu, and Zeng to its Advisory Board
HONG KONG, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Sky9 Capital, a leading China venture capital firm, announced that China industry veterans KS Chay, Dr. Kok Peng Teh, Bob Xu, and Jason Zeng have joined its Advisory Board to provide strategic advice and foster long-term partnerships.
KS Chay is Founder and Chairman of Enspire Capital, and previously he co-founded Singapore's first Nasdaq-listed technology company, Creative Technology Ltd (SGX:C76). Dr. Kok Peng Teh is currently Senior Advisor and Board Member for China International Capital Corporation, and he was President of Government of Singapore Special Investments (GIC) for over a decade until 2011. Mr. Bob Xu co-founded New Oriental Education & Technology Group (NYSE:EDU), the largest provider of private education in China, and is one of China's most successful angel investors having founded ZhenFund in 2010. Mr. Jason Zeng co-founded Tencent Holdings Ltd (HK:0700) and is currently Chairman of the angel-stage investment firm Decent Capital.
"We are honored to have industry veterans like KS Chay, Dr. Kok Peng Teh, Bob Xu, and Jason Zeng join our firm as our board of advisors," said Ron Cao, Founder and Managing Director of Sky9 Capital. "Mr. Chay and Dr. Teh come from a strong institutional approach to investing and can provide us with great guidance on how to continue to build out our organization. Bob and Jason are two of China's most successful entrepreneurs, so we gain great insights from their operational background as well as inspiration on how to build great businesses together with entrepreneurs."
Founded by China venture capital veteran Ron Cao, Sky9 Capital's mission is to partner with the next generation of entrepreneurs to create world-class companies that also have societal impact. With over 17 years of VC experience in both the US and China, Ron has invested in some of China's leading technology companies including: Tujia, China's largest AirBnB player; FangDuoDuo, China's largest online-to-offline real estate transaction platform; PPDai, China's largest pure-play microlending platform; and QingCloud, China's leading enterprise-grade cloud computing platform. Ron has been named by Forbes China as one of China's "Top Venture Capitalists" over multiple years and is honored by the World Economic Forum as one of its "Young Global Leaders".
Sky9 Capital's senior team consists of additional partners with strong venture capital and start-up experience. The team of Wei Hao, Jing Wang, Jonathan Qiu, and Tony Lo, have collectively over 30 years of venture capital experience in the US and China, and they previously worked at world-class technology companies such as Intel, Trilogy, Cisco, and Tencent. Their investments include PinDuoDuo, FaceU, Rong360, ZhaoGangWang, MaMaDaV, FangDuoDuo, JuMei, JingFuZhi, LuckyPai, and Dianping.
Sky9 Capital has completed six investments in its new fund, including ZhaoYouWang, the largest B2B marketplace for petroleum-related products in China; EZbuy, the leading Chinese cross-border e-commerce platform targeting the Southeast Asia market; and eBroker, the leading online platform for wealth management.
About Sky9 Capital
Sky9 Capital is a leading early-stage China-focused technology venture capital firm. With its mission to partner with bold innovators to build world-class companies together and to make a positive impact on the world, Sky9 Capital specializes in the consumer Internet, enterprise, and deep technology sectors. With presence in Beijing, Shanghai, Shenzhen, and Silicon Valley, our firm approaches investing with a global perspective and selectively partners with early-stage companies that have exceptional founding teams, disruptive and scalable business models, or innovative and transformational technology. For more information, please visit www.sky9capital.com.
Contact: Anthony Lo
Phone Number: +86-21-5238-3699
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sky9 Capital via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
Barings Supports New Mountain Capital Investment in DRB Systems17.10.2017 16:30 | Pressmeddelande
CHARLOTTE, N.C., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Barings, one of the world's leading asset management firms, announced today that it served as a Joint Lead Arranger on a Senior Secured Credit Facility to support New Mountain Capital's acquisition of DRB Systems LLC. Founded in 1984 and based in Akron, Ohio, DRB Systems is the leading provider of turnkey technology solutions used to enhance the operational efficiency of car wash sites across the U.S. DRB's integrated technology offering includes hardware and software used in point-of-sale and tunnel control systems as well as ancillary modules to support marketing, human resources, and business analytics. "New Mountain Capital is pleased to have completed its investment in DRB Systems," said Jack Qian, Director of New Mountain Capital. Laura Holson, Head of Capital Markets at New Mountain added, "We deeply value Barings' support as a financing pa
Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds17.10.2017 16:12 | Pressmeddelande
SANTA CLARA, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase their scientific expertise at this year's American Association for Cancer Research's International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) October 26th through the 30th. CrownBio's scientists will present 13 scientific posters describing their latest research efforts, including generation of novel models for combinatory chemotherapy and immunotherapy studies, creation of 3D screening panels for improved efficacy assessments, demonstration of a checkpoint immunotherapy modulating intestinal microbiota, among other innovative developments in cancer therapeutics and preclinical pharmacology evaluation. On
Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 201717.10.2017 15:15 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release third quarter 2017 financial results prior to market open on Tuesday, October 31, 2017. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 99539511, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations se
World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions17.10.2017 08:16 | Pressmeddelande
YOKOHAMA, Japan, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Today's press conference at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) featured groundbreaking findings in the study of both small cell and non-small cell lung cancer. The studies presented covered broad research areas, from confirmation of existing classification criteria to ensuring viability of evidence to supporting the use of specific interventions. Biopsy specimen found to be reliable for evaluating DLL3 expression in small cell lung cancer Small cell lung cancer (SCLC) biopsy specimen was found to be reliable material for evaluating DLL3 expression; high levels of DLL3 in SCLC are correlated with poor survival trends. These results may lead to further evaluation of the scoring system for predicting DLL3-targeted therapeutic efficacy and clinical significance of DLL3 expression in high-grade pulmonary neuroendocrine carcinomas.
New Era Launches Direct-to-Consumer eCommerce Site Built by EPAM and Powered with SAP Hybris17.10.2017 06:01 | Pressmeddelande
New Site Expands Headwear and Apparel Offering with Immersive, Omnichannel Experience NEWTOWN, Pa., Oct. 17, 2017 (GLOBE NEWSWIRE) -- EPAM Systems, Inc. (NYSE:EPAM), a leading global provider of digital platform engineering and software development services, and New Era, a global headwear brand rooted in sports, today announced the launch of New Era's first direct-to-consumer website, neweracap.com. New Era's B2B business remains strong, and the company is now putting an emphasis on selling its products directly to customers and expanding its offering into the lifestyle market. The new site offers products for seasoned athletes and sports fans, as well as street and lifestyle consumers. "In an age where businesses cannot tolerate lengthy, scope changing technology projects, EPAM quickly established themselves as the standout partner for us to tackle this ambitious initiative," said Lorenz Gan, Global Vice President, Information Technology, New Era. "Whilst this p
CP Kelco Appoints Didier Viala as New President16.10.2017 15:00 | Pressmeddelande
ATLANTA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- CP Kelco, a leading global producer of specialty hydrocolloid solutions, announced today that Didier Viala has been appointed President, effective October 1, 2017. Viala replaces Donald Rubright, who served as CP Kelco President since 2006 and will retire at the end of 2017. Viala has also joined the CP Kelco Board of Directors. "As a market leader supplying high-quality hydrocolloid products for a range of foods and beverages, consumer products and industrial applications, CP Kelco will continue to invest in capacity additions, new product and applications development, strategic raw material sourcing, quality and safety management, and sustainability initiatives to support our customers' innovation efforts and growth strategies," Viala said. Over the course of more than 25 years with CP Kelco and its predecessor companies, Viala held leadership roles across a broad spectrum of critical areas, including innovat
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum